Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1476-1483

  MacCallum, Donna M ^b   Coste, Alix ^a   Ischer, Françoise ^a   Jacobsen, Mette D ^b   Odds, Frank C ^b   Sanglard, Dominique ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GLYCOPROTEIN P; PYRROLE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CDR1 GENE; CDR2 GENE; CHROMOSOME SUBSTITUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; FUNGAL GENE; FUNGAL GENETICS; FUNGAL STRAIN; GENE FREQUENCY; GENE MUTATION; GENETIC MANIPULATION; GENETIC RESISTANCE; GENETIC TRANSCRIPTION; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; TAC1 GENE; UPREGULATION; WILD TYPE;

ANIMALS; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA ALBICANS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DNA PRIMERS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; GENES, FUNGAL; GENETIC ENGINEERING; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 77950180902     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01645-09     Document Type: Article

References (31)

1. Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
2. Boerlin, P., F. Boerlin-Petzold, J. M. Goudet, C. Durussel, J. L. Pagani, J. P. Chave, and J. Bille. 1996. Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. J. Clin. Microbiol. 34:1235-1248.
3. Chau, A. S., M. Gurnani, R. Hawkinson, M. Laverdiere, A. Cacciapuoti, and P. M. McNicholas. 2005. Inactivation of sterol Δ5,6-desaturase attenuates virulence in Candida albicans. Antimicrob. Agents Chemother. 49:3646-3651.
4. Coste, A., J. Crittin, C. Bauser, B. Rohde, and D. Sanglard. 2009. Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot. Cell 8:1250-1267.
5. Coste, A., A. Selmecki, A. Forche, D. Diogo, M. E. Bougnoux, C. d'Enfert, J. Berman, and D. Sanglard. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6:1889-1904.
6. Coste, A., V. Turner, F. Ischer, J. Morschhäuser, A. Forche, A. Semelcki, J. Berman, J. Bille, and D. Sanglard. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139-2156.
7. Coste, A. T., M. Karababa, F. Ischer, J. Bille, and D. Sanglard. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652.
8. Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2003. A point mutation in the 14α-sterol demethylase gene Cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
9. Dunkel, N., J. Blass, P. D. Rogers, and J. Morschhäuser. 2008. Mutations in the multidrug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840.
10. EUCAST-AFST (European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing). 2008. EUCAST technical note on fluconazole. Clin. Microbiol. Infect. 14:193-195.
11. EUCAST-AFST (European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing). 2008. EUCAST technical note on voriconazole. Clin. Microbiol. Infect. 14:985-987.
12. Louie, A., G. L. Drusano, P. Banerjee, Q. F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
13. MacCallum, D. M., L. Castillo, A. J. P. Brown, N. A. R. Gow, and F. C. Odds. 2009. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One 4:e6420.
14. MacCallum, D. M., L. Castillo, K. Nather, C. A. Munro, A. J. P. Brown, N. A. R. Gow, and F. C. Odds. 2009. Property differences among the four major Candida albicans strain clades. Eukaryot. Cell 8:373-387.
15. MacCallum, D. M., and F. C. Odds. 2005. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48:151-161.
16. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, W. J. Melchers, P. E. Verweij, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
17. Morschhäuser, J., K. S. Barker, T. T. Liu, B. W. J. Bla, R. Homayouni, and P. D. Rogers. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164.
18. Murad, A. M., P. R. Lee, I. D. Broadbent, C. J. Barelle, and A. J. Brown. 2000. CIp10, an efficient and convenient integrating vector for Candida albicans. Yeast 16:325-327.
19. Odds, F. C., M. E. Bougnoux, D. J. Shaw, J. M. Bain, A. D. Davidson, D. Diogo, M. D. Jacobsen, M. Lecomte, S. Y. Li, A. Tavanti, M. C. Maiden, N. A. Gow, and C. d'Enfert. 2007. Molecular phylogenetics of Candida albicans. Eukaryot. Cell 6:1041-1052.
20. Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T. F. Patterson. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
21. Perea, S., J. L. Lopez-Ribot, B. L. Wickes, W. R. Kirkpatrick, O. P. Dib, S. P. Bachmann, S. M. Keller, M. Martinez, and T. F. Patterson. 2002. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 46:1695-1703.
22. Pinjon, E., G. P. Moran, C. J. Jackson, S. L. Kelly, D. Sanglard, D. C. Coleman, and D. J. Sullivan. 2003. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 47:2424-2437.
23. Rodero, L., E. Mellado, A. C. Rodriguez, A. Salve, L. Guelfand, P. Cahn, M. Cuenca-Estrella, G. Davel, and J. L. Rodriguez-Tudela. 2003. G484S amino acid substitution in lanosterol 14-α demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob. Agents Chemother. 47:3653-3656.
24. Sanglard, D., A. Coste, and S. Ferrari. 2009. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 9:1029-1050.
25. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contributing to the resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42: 241-253.
26. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC-transporter gene. Microbiology 143: 405-416.
27. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
28. Selmecki, A., M. Gerami-Nejad, C. Paulson, A. Forche, and J. Berman. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 68:624-641.
29. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
30. Wirsching, S., S. Michel, and J. Morschhäuser. 2000. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol. 36:856-865.
31. Xiao, L., V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. McNicholas. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574.